Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT (P1-11.004)
The phase 3b ADAPT NXT study (NCT04980495) investigated the efficacy, safety, and tolerability of efgartigimod administered either every other week (Q2W) or in fixed-cycle dosing regimens.
Authors
- Elena Cortés‐Vicente (ORCID: https://orcid.org/0000-0002-1428-1072)
- Fang Sun (ORCID: https://orcid.org/0000-0002-3089-2244)
- Deborah Gelinas
- Edward Brauer
- Renato Mantegazza (ORCID: https://orcid.org/0000-0002-9810-5737)
- Kelly Gwathmey (ORCID: https://orcid.org/0000-0002-7589-8826)
- Kristl G. Claeys (ORCID: https://orcid.org/0000-0001-9937-443X)
- Andreas Meisel (ORCID: https://orcid.org/0000-0001-7233-5342)
- Gregory Sahagian (ORCID: https://orcid.org/0000-0002-3893-4920)
- Vera Bril (ORCID: https://orcid.org/0000-0002-5805-4883)
- Shahram Attarian (ORCID: https://orcid.org/0000-0002-7211-4694)
- Li Liu (ORCID: https://orcid.org/0000-0002-0303-3241)
- Ali A. Habib (ORCID: https://orcid.org/0000-0003-3432-9747)
- Delphine Masschaele
- Jeff Guptill
- Yessar Hussain
- Rosa H. Jimenez
Institutions
- University Health Network (CA)
- Virginia Commonwealth University (US)
- Hospital de Sant Pau (ES)
- Health Net (US)
- University of California System (US)
- Neurology Center of Southern California (US)
- Argenx (Belgium) (BE)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210664
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00